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Abstract
Background: Smoking tobacco remains the most significant modifiable cause of adverse pregnancy outcomes and contributor
to ongoing maternal and infant ill-health. Pregnancy for many is a time of heightened health focus, with the primary motivation
being the well-being of the unborn child. Yet, many women continue to smoke throughout their pregnancy. Despite this heightened
motivation and known health risks, interventions to date have not effectively curbed the rate of smoking during pregnancy and
they remain as high as rates among the general population. One promising strategy has been to incentivize these women to quit.
However, incentives-based studies have not shown or reported long-term efficacy. Here, we present the protocol of a trial exploring
the effect of incentivized partner support on pre- and postpartum smoking cessation.
Objective: The aim of this study is to determine whether providing incentives to both the expectant mother and her support
person in promoting short- and long-term smoking cessation during pregnancy is more effective than incentives to the expectant
mother alone.
Methods: This protocol is designed as a non-randomized, single-blinded trial to determine the efficacy of incentivized partner
support, compared to participant incentive only, in promoting smoking cessation during pregnancy and postpartum. All eligible
pregnant women receiving antenatal care via the Tasmanian Health Service (Australia) will be invited to participate. Participants
will be eligible for monthly quit-contingent shopping vouchers if they verify, via carbon monoxide breath sample, as being
abstinent from smoking. Participating women will be eligible for vouchers until 6-months postpartum and will be followed up at
12-months postpartum.
Results: The recruitment phase of this study has concluded. Results are expected to be published by the end of 2018.
Conclusions: This study protocol extends the current literature on incentivized smoking cessation interventions for pregnant
women by assessing the influence of incentivizing a support partner on short- and long-term abstinence. Key ethical considerations
are discussed including potential for receipt (or not) of quit-contingent vouchers impacting negatively on the participant’s
relationship with their partner. The findings of the study may have important implications for the role support partners are assigned
in smoking cessation programs targeting pregnant women.
Trial Registration: Australian New Zealand Clinical Trials Registry (ACTRN): 12615001158550; https://www.anzctr.org.au/
Trial/Registration/TrialReview.aspx?id=367981 (Archived by WebCite at http://www.webcitation.org/6tGKO28uh)
(JMIR Res Protoc 2017;6(10):e209)   doi:10.2196/resprot.7907
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Introduction
Smoking and Perinatal Health
Smoking during pregnancy is recognized as the single most
modifiable cause of poor pregnancy outcomes [1] and the risks
to mother and baby have been reported extensively elsewhere
[2]. Briefly, these risks include increased risk of miscarriage,
preterm birth, low birth weight, major congenital abnormalities,
and sudden infant death syndrome [2,3]. Less known long-term
effects as a result of prenatal smoke exposure include increased
risk of reduced neuromotor function, attention deficit
hyperactivity disorder (ADHD), learning difficulties, and
behavior dysregulation during childhood and adolescence [4-7].
Infant exposure to second-hand smoke has also been shown to
further compound these negative health consequences [2].
Despite these known risks, many women continue to smoke
during and after pregnancy, at rates comparable to the general
smoking population [8,9]. Even when women manage to quit
during pregnancy, most (up to 80%) relapse within 6 months
of delivery [10]. Rates are considerably and consistently higher
among certain already disadvantaged cohorts including young
expectant mothers (in Australia, 34% of pregnant women 20
years or younger smoke) and women living in rural and remote
areas (37% in Australia) [11]. More effective, targeted
interventions are clearly needed for this high-risk group.
Interventions for Promoting Cessation Among
Pregnant Smokers
One of the most effective strategies for promoting smoking
cessation among pregnant women is incentives-based
interventions [12,13]. Providing incentives for pregnant smokers
to quit has been shown to not only increase abstinence rates
several-fold compared to any other type of treatment, but also
to increase mean birth weight [12,14]. Further, in a review of
the most common interventions (including cognitive behavior
therapies, stages of change, feedback, pharmacotherapies, and
other therapies), incentives-based programs were found to be
the most cost-effective, producing a net cost benefit of US $3482
after factoring in intervention costs [12,15,16]. Incentives-based
programs for pregnant smokers appear to promote successful
postpartum abstinence rates (approximately 25% abstinent at 3
to 6 months postpartum), but since few studies have included
long-term postpartum follow-up, the long-term efficacy is not
well understood [17]. While one study reported a 12-month
postpartum follow-up with promising cessation rates (0% to
44% depending on model of care), this study included
participants who had quit within 1 month of enrolment, and thus
the effectiveness of incentives-based interventions at promoting
long-term abstinence remains unclear [18].
Partner Support and Sustained Cessation
In a review of postpartum relapse prevention strategies,
programs that involved the pregnant smoker’s partner were
deemed necessary to maximize long-term cessation success
[19]. To date, only one randomized controlled trial (RCT) has
been conducted to examine the effect of partner support [20].
Participants were randomized to 3 groups: usual care, counseling
support (6 counseling telephone calls; 3 during pregnancy, 3
postpartum), and counseling support combined with
partner-support facilitated by a tailor-made “it takes two”
booklet and video (partner was usually baby’s father who was
also provided 6 separate counseling support telephone calls).
No significant difference in participants’ smoking behavior was
found between the groups. Interestingly, the authors found that
positive support (behaviors characterized by cooperation and
reinforcement of quitting behavior such as “compliment you
on not smoking”) diminished linearly from baseline to 12
months postpartum and negative support (behaviors
characterized by nagging and policing such as “comment on
your lack of willpower”) decreased through pregnancy before
increasing again postpartum.
The importance of the quality of support provided in partner
support interventions has been found to be critical in promoting
cessation among non-pregnant smokers [21]. In a study
exploring the effect of positive and negative support behaviors
on quit rates among female smokers, Cohen and Lichtenstein
showed that women who reported receiving a higher ratio of
positive supportive behavior compared to negative (using a
shortened version of the Partner Interaction Questionnaire) from
their spouse were more likely to quit. This emphasis on quality
of support may explain why other studies found no effect for
partner support [20-22].
Combining incentives programs with partner support,
particularly the co-habiting and/or romantic partner (eg,
expectant father) that emphasizes positive support, may therefore
be an approach that fosters more effective long-term cessation
for pregnant smokers. To our knowledge, only one study to date
has explored incentivizing social support to promote smoking
cessation in pregnant women. Donatelle and colleagues [23]
compared 2 groups: 1 receiving usual antenatal care and 1 which
included both the women and their chosen female non-smoking
supporter (providing unstandardized, non-formalized, “natural”
peer support only) provided with quit-contingent shopping
vouchers. Participants in the incentivized partner support group
were more likely to be quit at the end-of-pregnancy (32% versus
9%) and at the 2-month postpartum (21% versus 6%) time points
compared to usual care. Since this study was not fully factorial
(eg, intervention groups consisting of social support only and
incentives only, not included), the effect of partner support over
and above incentives could not be determined. Furthermore,
the support person in the Donatelle et al [23] study was not the
pregnant women’s spouse (eg, husband and/or father of child),
but rather a female, non-smoking friend, who might arguably
have had less vested interest in the health of the expectant child
than the expectant father.
Objectives
The purpose of this study is to determine whether providing
incentives to both support person and expectant mother, if she
is able to quit smoking, is more effective than providing
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incentives to expectant mother only, in promoting short- and
long-term smoking cessation during pregnancy. In essence, the
present study seeks to answer the question: “Can partners (eg,
spouse) be incentivized to be more supportive and effective quit
buddies to their pregnant smoking partners?”
Specifically, the study aims to determine whether (1) providing
an incentive to both the support partner and expectant smoking
mother to quit is more effective than providing an incentive to
the pregnant smoker alone at promoting abstinence; (2)
regardless of incentives, women who receive more positive
cessation support from their partners, as measured by the Partner
Interactive Questionnaire 20 (PIQ-20), are more likely to quit
smoking; and (3) providing incentives for pregnant smokers to
quit is more effective than “usual care” antenatal quit smoking
services such as brief advice and referral to smoking cessation
services (external telephone counseling and smoking cessation
nurse) at promoting smoking cessation.
The primary outcome for the study is smoking status (ie,
smoking or quit), as determined by self-report 7-day point
prevalence, and carbon monoxide (CO) less than 7 particles per
million (ppm) at the end-of-pregnancy time point. Secondary
outcomes include effect of incentives on long-term (2 months
and 12 months postpartum) abstinence and influence of the
quality of partner support (positive compared to negative
supportive behaviors) on smoking status.
Methods
Trial Design
This study will adopt a non-randomized, single-blinded,
controlled 2-group (control and treatment) trial design.
Participant Recruitment
All eligible pregnant women who smoke and live in Tasmania
(Australia) are invited to participate in the study. Statewide
recruitment is facilitated by drawing on data from the Tasmanian
Health Service’s digital medical record (DMR) and encompasses
multiple strategies to maximize reach. A research midwife, with
access to the Tasmanian Health Service’s DMR, conducts “cold
calling” of all women who self-reported smoking in the last 7
days during their initial antenatal “booking in” appointment
(usually around 10 weeks gestation). Using information stored
on the DMR, the midwife pre-screens women for eligibility (eg,
self-report smoking, 16 years or older) and telephones them to
invite them to participate in the study. With their verbal consent,
the details of interested women are recorded and forwarded to
the research team.
Antenatal staff of the Tasmanian Health Service (including
physicians and midwives) provide study information (in the
form of a flyer) to eligible participants during antenatal
appointments. With their consent, the contact details of
interested women are forwarded to the research team. In
addition, the study is advertised through flyers placed in general
practitioner (GP) clinics, outreach centers and community hubs
across Tasmania. Informal advertising via social media (eg,
Facebook) and television and radio interview exposure may
also be utilized. Consequently, potential participants could also
self-refer to the study by contacting the researchers directly.
Eligibility Criteria
Women who express interest in participating in the study (either
self-refer or consent to a health professional forwarding their
contact details to research staff) are contacted by research staff
and screened for eligibility using a previously validated protocol
[24]. To be eligible for study entry, women must be (1) pregnant
(20 weeks gestation or less); (2) at least 16 years of age; (3)
self-report as being a current smoker (“even a single puff in the
last 7 days”); (4) attending routine antenatal care provided by
the Tasmania Health Service or participating GP center
(Tasmanian, Australia); and (5) be able to attend a minimum
of 3 appointments at 1 of the 3 data collection sites across
Tasmania (Launceston General Hospital, Royal Hobart Hospital,
or Mersey Community Hospital). Women younger than 18 years
(but 16 years or older) require the consent of their parent,
guardian, or senior antenatal health provider to participate in
the study.
Potential participants are excluded from study entry if they
self-report as non-smoking (ie, “have not smoked, even a single
puff in last 7 days”) or if they have a cognitive or intellectual
impairment that will inhibit fulfillment of participation
requirements (eg, completion of surveys and/or attend organized
study appointments). Participants who are found to be “gaming”
(eg, those who tell researchers they are pregnant and/or smoking
untruthfully to enroll in study) are also excluded from further
participation and their data discarded. All participants are asked
to nominate and are encouraged to bring along to study visits a
support person, preferably a person they co-habit with (eg,
spouse, father of child, or family member).
Assignment of Interventions
Participants are assigned to the same group (either control or
the treatment group) for 3 consecutive months (interchangeably
for 18 months), such that participants recruited in the first 3
months are allocated to the control group and participants
recruited in the following 3 months are allocated to the treatment
group. This design was chosen to assist participant blinding to
group allocation, given the heightened potential for the women
recruited to know each other and/or discuss research
participation. Since participants in this study are recruited
following their first antenatal appointment, participants recruited
around the same time will have similar due dates. As
membership to parents’ groups and hospital-run parentcraft
classes is usually assigned by due date/gestation, and due to the
relatively small recruitment pool (Tasmania has a population
of 515,000 and only 3 tertiary hospitals), adopting a fully
randomized, parallel group controlled design would likely
jeopardize participant allocation concealment (ie, differing
incentive amounts), thus introducing bias (eg, recruited women
declining/delaying enrolment due to allocation, participants not
being as motivated to quit smoking due to lesser incentive
amount). As well as assigning participants to the same group
in 3-month intervals, participants who report knowing another
participants or are recruited by another participant are assigned
to the same group.
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Interventions
During their initial enrolment visit (visit 1), all participants and
their support partners are offered a separate resource pack
providing further information and quit references. The content
of the packs, selected on the basis of existing resources
developed and distributed by not-for-profit organizations and
government-funded bodies (eg, Quitline, Cancer Council, and
SIDS and Kids), includes informational brochures on the topics
of smoking and pregnancy, quitting smoking during pregnancy,
a guide for quitting smoking, and smoking and sudden infant
death syndrome. A referral and resources summary list (eg,
further websites and available mobile phone apps) is also
provided that includes telephone numbers of local counseling
services. The resource pack specifically designed for partners
contains information about the effect of second-hand smoke on
children, quit smoking products, and how to be an effective quit
buddy. Following the single-blinded, consecutive-month
schedule, women are allocated to either the control or treatment
group during their enrolment session (Textbox 1).
Textbox 1. Control and Treatment group incentives.
Group
• Control
• Only the participant is rewarded with a AUD $50 voucher if they verify as quit during monthly visits
• Treatment
• Both participant (1 x AUD $50) and their designated support person (1 x AUD $50) receive a shopping voucher if the participant verifies
as quit during monthly visits
• If partner is not present during study visits, participant collects both vouchers
All participants are encouraged to make a quit attempt in the 2
weeks following the enrolment visit in order to promote quit
status (verified by less than 7 ppm CO breath sample) and enable
incentive issue at the first monthly follow-up, although it is
emphasized that each participant is able to decide their own quit
timeframe and approach. No other formal smoking cessation
counseling support is provided.
All participants are asked to attend 2 further study visits—visit
2 (end-of-pregnancy) and visit 3 (end-of-study)—and have the
opportunity to attend monthly visits to verify their non-smoking
status and receive incentive voucher/s.
Quit-Contingent Incentive Vouchers and Study
Compensation
All participants attending a scheduled visit are provided with
some form of voucher compensation. For participants who are
still smoking, an AUD $10 voucher is offered. Participants who
verify as quit are offered the shopping voucher amount
consistent with their group allocation. If a participant is not
abstinent at any visit during pregnancy, they are still eligible to
receive the quit-contingent incentive at any subsequent visit
during pregnancy if they provide a CO reading of less than 7
ppm.
Verification of Smoking Status
During each visit and telephone call, participants are asked if
they have smoked, even a single puff, in the last 7 days. During
study visits, participants complete a 14-day timeline follow-back
questionnaire as an assessment of self-reported smoking. To
verify self-report, all participants are required to provide 2
expired air CO samples using a piCO Simple Smokerlyzer [25].
Expired CO was chosen as the most appropriate biochemical
verification method in this study as it is not sensitive to the use
of nicotine-containing medication (such as nicotine replacement
therapy which may be used by participants), is non-intrusive,
immediate (facilitates immediate provision of quit-contingent
incentive vouchers), and inexpensive. The CO readings are
recorded and if the average of the 2 samples is less than 7 ppm,
the participant’s smoking status is recorded as quit and she
receives a voucher incentive. A cut-off value of less than 7 ppm
was selected based on recommendations from the National
Institute of Health and Care Excellence [15], in addition to the
precedent set by existing research in the field which accounts
for likely second-hand smoke exposure (eg, from support
partner) [18,26]. To check whether our results are sensitive to
the CO cut-off value, we also repeat our primary analysis using
a CO level of less 4 ppm as the cut-off for abstinence.
Substantial discrepancies between the results obtained with the
2 cut-off values suggests that participants are “gaming” the
system (that is, continuing to smoke but cutting down just
enough to receive the abstinence reimbursement). Based on
results of previous similar studies [27], we do not expect
“gaming” among participants for incentives to be a significant
issue.
Procedure
Study Visits and Follow-Up Calls
A schematic diagram summary of the time-schedule of visits,
rewards, and data collection at each visit is shown in Multimedia
Appendix 1.
Enrolment Visit
During the enrolment visit (visit 1) participants are asked to
complete a battery of questionnaires and provide 2 CO breath
samples. Regardless of group allocation, participants are asked
to nominate a support person (they are asked to have this person
in mind when completing the Partner Interaction Questionnaire),
preferably the person they are living with (eg, partner or family
member), whose contact details are recorded along with the
participant’s own details to assist with future correspondence.
While no smoking cessation counseling is provided, participants
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are offered a resource pack for themselves and their support
partner.
End-of-Pregnancy Visit
Regardless of smoking status, all participants are required to
attend an end-of-pregnancy study visit. This second visit occurs
at approximately 8 months gestation and participants are asked
to provide 2 CO samples and complete a series of questionnaires.
End-of-Study Visit
Regardless of smoking status, all participants are required to
attend an end-of-study visit, which occurs at approximately 2
months postpartum. Participants are asked to provide 2 CO
samples and complete a series of questionnaires including the
End-of-Study Questionnaire.
Monthly Telephone Calls and Verification Visits
Monthly telephone calls are conducted with all participants to
determine smoking status. During the phone calls, participants
are asked “Have you had a cigarette (even a puff) in the past 7
days?” If a participant self-reports as abstinent, they are invited
to attend a follow-up verification visit to verify their smoking
status (and receive a voucher incentive), which is booked at
their next convenience. If the participant self-reports smoking
in the last 7 days during the monthly telephone call, they are
advised that they are not eligible for the incentive that month
and will be contacted again the following month. This monthly
payment schedule limits the additional participation burden on
participants, and where possible, is scheduled on days when
they are attending routine hospital antenatal appointments. This
monthly payment schedule was also utilized by the only other
study published using incentivized partner support [23].
Participants who verify as abstinent at their end-of-study visit
(visit 3) are eligible to receive monthly calls and incentives until
6 months postpartum. Participants who are still smoking at the
end-of-study visit no longer receive monthly calls (and are
ineligible for any further incentives) from that date. Multiple
(up to 5) attempts are made to contact each participant for their
scheduled monthly telephone calls and visits. Text messages
(short message service, SMS) are also utilized to try to contact
those difficult to reach. However, the study adopts an
intention-to-treat approach such that if participants become
un-contactable at any time throughout the study, it is presumed
they are smoking [28].
12-Month Telephone Call and Visit
Each participant, regardless of smoking status, is contacted via
telephone 12 months after the delivery of their baby. The
12-Month Follow-Up Questionnaire is administered via
telephone and participants are asked their current smoking status.
Participants who self-report abstinence (7-day point prevalence)
during this call are invited to verify smoking abstinence via a
CO breath sample in a follow-up visit and be offered an
AUD$10 shopping voucher (regardless of verification status)
to thank them for their participation. This marks the completion
of their participation in the study.
Study Questionnaires
A battery of questionnaires are issued to participants during
study visits.
Baseline Questionnaire
The Baseline Questionnaire was developed to obtain
demographic information (eg, age, highest level of education,
income), information about smoking characteristics (eg, smoking
status, cigarettes per day, dependence [Fägerstrom Test for
Cigarette Dependence [29]], smoking history, and partner’s
smoking characteristics), and pregnancy (eg, gestation, gravidity,
smoking during previous pregnancies). This questionnaire is
administered only once at study enrolment (visit 1).
Smoking Knowledge Quiz
The Smoking Knowledge Quiz was developed from existing
publicly available and scientifically reliable smoking information
and is similar to the questionnaire used in a previous study [30].
The quiz requires participants to answer questions regarding
their knowledge of the safety and effectiveness of smoking
cessation treatments and techniques during pregnancy, as well
as the health risks associated with cigarette smoking for
themselves and their baby. Participants’ responses to this quiz
are reviewed with the participant at the time of the enrolment
visit to prompt discussion of health risks and available cessation
aids. The quiz is administered once only at study enrolment
(visit 1).
Smoking Status Questionnaire
The Smoking Status Questionnaire is a self-report, 14-day
cigarette timeline follow-back which requires participants to
report the number of cigarettes smoked each day for the previous
2-week period [31]. This questionnaire is completed at each
study visit.
Reasons for Quitting Questionnaire
The Reasons for Quitting Questionnaire (RFQ) is a 24-item
questionnaire measuring an individual’s motivation for quitting
[32]. Reponses to items such as “I want to quit smoking because
I am concerned that I will suffer from a serious illness if I don't
quit” are scored on a 5-point Likert scale from 0 (not at all true),
to 4 (extremely true). This questionnaire is completed at each
study visit.
Partner Interaction Questionnaire
The Partner Interaction Questionnaire (PIQ) is used to gather
information about the level of partner support [33]. It includes
10 positive (PIQ-POS) (eg, “Express pleasure at your efforts to
quit”) and 10 negative (PIQ-NEG) (eg, “Comment on your lack
of willpower”) partner behaviors that could be expressed towards
a quitting partner. This questionnaire is completed at each study
visit.
End-Of-Study Questionnaire
The End-of-Study Questionnaire was developed to collect
information after participants have had their baby and is
conducted around 2 months postpartum during the scheduled
end-of-study visit (visit 3). This questionnaire includes questions
about smoking status, cigarettes per day, experience of study
participation and receiving incentives, treatments/methods used
to aid quit attempt, partner support, and partner smoking status,
as well as any birth complications experienced.
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12-Month Follow-Up Questionnaire
The 12-Month Follow-Up Questionnaire is administered via
telephone during the 12-month follow-up telephone interview.
This marks the completion of study participation. Participants
are asked to describe their smoking status, experience of being
in the study, details of partner support of quit attempts, and their
overall general well-being and that of their baby. If participants
are quit, they are invited to return to the study center to verify.
Fetal growth and birth outcomes are also collected from babies
of consenting participants (a separate consent form is provided
seeking access to this information) including head
circumference, femur length, heart/vascular data, birth weight,
Apgar score (overall health at birth), gestational age, and digital
medical records of neonatal intensive care unit (NICU) or
respiratory admissions (if applicable). These data will be used
for exploratory analyses to determine any associations with
intervention effects.
Sample Size and Checks
The study is powered on the primary hypothesis (H1) which
requires a sample size of 108 (see below). This is consistent
with a review of previous research in the area, which revealed
sample sizes ranging between 40 and 220 with approximately
equal group sizes [17]. To ensure particular features of the study
protocol do not influence the data, checks will be conducted
during the analysis phase to control for influence of different
antenatal service sites being used for recruitment and testing,
as well as any cyclical effects of the cyclical monthly
recruitment design.
Planned Analyses
Analyses are planned to test each of the 4 hypotheses.
Hypothesis 1
The first hypothesis (H1) is that providing an incentive to both
the support partner and expectant smoking mother to quit is
more effective than providing an incentive to the pregnant
smoker alone at promoting abstinence during pregnancy.
The quit rates of the treatment and control groups will be
compared at the end-of-pregnancy time point (visit 2) using
chi-square analysis. While no study to our knowledge has
compared participant-only incentive with combined participant
and support partner incentive, Donatelle et al [23] compared a
usual care control group with an incentive plus partner incentive
treatment group and found that at the end-of-pregnancy, 32%
of treatment group participants had quit (n=105) compared with
9% in the control group (n=102), which indicates a large effect
size (χ2=18.4, N=207, d=0.62) [23]. Since the control group in
the present study is also receiving incentives, it is anticipated
that the effect size may be moderate, rather than large. As such,
to determine if there is a significant difference in proportion of
women who have quit between control group and treatment
group, with the power of .80 to detect an effect size of 0.30, the
study will require a total sample size of 108.
Hypothesis 2
The second hypothesis (H2) is providing an incentive to both
the support partner and expectant smoking mother to quit is
more effective than providing an incentive to the pregnant
smoker alone at promoting abstinence in the postpartum period.
As per H1 above, treatment and control group abstinence rates
will also be compared at the end-of-study (visit 3) and at
12-months postpartum follow-up time points to determine the
effect of incentivized partner support on postpartum abstinence.
A multi-comparison adjustment will be applied to control for
family-wise error.
Hypothesis 3
The third hypothesis (H3) is regardless of incentives, women
who receive more positive cessation support from their partners
(as measured by PIQ-20) are more likely to quit smoking.
Participants, regardless of group allocation, will be regrouped
to either PIQ-POS or PIQ-NEG, as determined by the ratio of
positive compared to negative support they report receiving
from their support partners. The abstinence rates of these
regrouped PIQ-POS and PIQ-NEG participants will then be
compared at 3 time points; end-of-pregnancy, end-of-study (2
months postpartum), and 12 months postpartum.
Hypothesis 4
The fourth hypothesis (H4) is providing incentives for pregnant
smokers to quit is more effective than “usual care” antenatal
smoking cessation support at promoting smoking cessation.
The quit rates of participating women will be compared to the
average quit rate of a historical control of women receiving
antenatal care by the Tasmanian Health Service from 2011 to
2015 [34].
Results
The recruitment phase of the study has concluded and
postpartum data collection is ongoing. Data collection is
anticipated to be complete by late 2017. Outcomes of the trial
will be published within a year (12 months) of completing final
12-month follow-up data collection. The study results will be
disseminated via conference presentations and papers published
in academic peer-reviewed journals. The participants, healthcare
professionals, and public will be informed of the study results
through email correspondence and local media.
Discussion
The project has been reviewed and approved by the Tasmanian
Health and Medical Research Ethics Committee (H0014568).
Prior to enrolling in the study, all participants provide verbal
and written consent. Furthermore, additional checks are
conducted throughout the study to ensure participant safety in
light of details receiving particular attention during the ethical
review process. The first is the risk of a negative impact of the
receipt (or not) of quit-contingent shopping vouchers on the
study participant’s relationship with their partner, with the
concern that this may be a potential trigger for family violence
or other threat to the safety of the woman (and/or unborn child).
During each study visit or telephone call, participants are asked
if study participation is impacting negatively on their
relationship with their partner. If real or perceived risk is present,
JMIR Res Protoc 2017 | vol. 6 | iss. 10 | e209 | p.6http://www.researchprotocols.org/2017/10/e209/
(page number not for citation purposes)
Frandsen et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
the study research officer ensures the safety of the participant
by making urgent contact with and referral to the antenatal
Social Work service (or after-hours emergency/crisis social
work service) at the relevant public hospital to arrange safe
accommodation and other services as indicated. The second is
the risk of potential distress should a participant experience
adverse pregnancy or other outcomes (eg, fetal or infant death)
while involved in the study. The research midwife conducts
monthly checks of participants’ pregnancy and health status via
the Tasmanian Health Service’s digital medical records. In these
rare occasions, no further contact is initiated with the participant
and her involvement and data is withdrawn. However, should
the participant request to continue to participate, she is welcome
to do so.
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